Biopharmaceutical company Omeros has appointed Michael Jacobsen as vice president of finance and chief accounting officer.

Jacobsen, who joins Omeros with over 30 years of business management and accounting experience, most recently served a vice president of finance and CAO at Sarepta Therapeutics (formerly AVI BioPharma). From 2007 to 2011, he served as vice president and CAO at biotechnology company ZymoGenetics, which was acquired by Bristol-Myers Squibb in 2010. In this role, he was responsible for managing all aspects of accounting and financial information, tax planning and compliance, SEC reporting, annual audit and quarterly reviews, and purchasing.

Prior to ZymoGenetics, Jacobsen held various roles from 2001 to 2007 at biotechnology company ICOS, a publicly traded biotechnology company acquired by Eli Lilly in January 2007. Previously, Jacobsen held the position of vice president of finance and CFO at two publicly traded e-commerce and software companies.